A Phase 3 interventional study of PTX-022 in Pachyonychia Congenita, sponsored by Palvella Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.
Sponsored by Palvella Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
VALO-2 is a multicenter, open-label extension (OLE) study enrolling patients with genotyped keratin mutations KRT6A, KRT6B and KRT16 who were previously treated with investigational PTX-022 during the VALO study. The purpose of the OLE study is to investigate long term exposure to investigational PTX-022 and evaluate safety and efficacy data. A sub-study is included to evaluate safety and efficacy of patients with genotyped keratin mutations of KRT6C and KRT17 not previously treated with investigational PTX-022.
Palvella Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PTX-022 QTORIN
Drug: PTX-022
Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita
Incidence of Treatment-Emergent Adverse Events
Time frame: 18 Months
Changes in vital sign measurements from baseline
Time frame: 18 months
Changes in weight measurements from baseline
Time frame: 18 months
Changes in clinical laboratory measurements from baseline
Time frame: 18 months
Patient Global Assessment of Activities Scale
Time frame: 18 Months
Pain at its worst as assessed by NRS
Time frame: 18 months
PROMIS Pain Interference Short 6A as assessed by likert scale
Time frame: 18 months
PROMIS Physical Function as assessed by likert scale
Time frame: 18 months
Patient Global Impression of Severity as assessed by likert scale
Time frame: 18 months
Clinician Global Impression of Severity as assessed by likert scale
Time frame: 18 months
Ran from Sep 2020 to primary completion in Jun 2021, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus Topical Gel PTX-022
Pachyonychia Congenita
Palvella Therapeutics, Inc.